Thomson ReutersA sign sits in front of Shire’s manufacturing facility in Lexington, Massachusetts
Some Wall Street analysts expressed disappointment with a promise of annual operating cost savings of over $500 million.
However, Flemming Ornskov, chief executive of Dublin-based Shire, said his style is to under promise and over deliver.
“Our internal synergy goals are much higher,” he said at the annual JP Morgan Healthcare Conference in San Francisco.
He also said the agreement that ended a six-month pursuit of Baxalta was not driven by cost savings or lower taxes. “This is a growth play,” he said.
(Reporting by Bill Berkrot; Editing by Bernard Orr)
Read the original article on Reuters. Copyright 2016. Follow Reuters on Twitter.
More from Reuters:
- Not his lucky day – Texan falls in hole on way to buy lottery ticket
- U.S. judge orders woman in debunked rape story to turn over papers: report
- Racism, accountability top concerns at hearing on Chicago’s new top cop
- China December exports fall 1.4 percent, less than forecast
- Saudi Arabia, U.S. still in talks about U.S. warship deal: sources
